Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene

Authors: Kirstin Mittelstrass, Wiebke Sauter, Albert Rosenberger, Thomas Illig, Maria Timofeeva, Norman Klopp, Hendrik Dienemann, Eckart Meese, Gerhard Sybrecht, Gabi Woelke, Mathias Cebulla, Maria Degen, Harald Morr, Peter Drings, Andreas Groeschel, Karsten Grosse Kreymborg, Karl Haeußinger, Gerd Hoeffken, Christine Schmidt, Bettina Jilge, Wilhelm Schmidt, You-Dschun Ko, Dagmar Taeuscher, Jenny Chang-Claude, Heinz-Erich Wichmann, Heike Bickeboeller, Angela Risch

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

The polymorphism SNP309 (rs2279744) in the promoter region of the MDM2 gene has been shown to alter protein expression and may play a role in the susceptibility to lung cancer. The MDM2 protein is a key inhibitor of p53 and several mechanisms of MDM2/p53 interactions are presently known: modulating DNA-repair, cell-cycle control, cell growth and apoptosis.
We used 635 Caucasian patients diagnosed with lung cancer before 51 years of age and 1300 healthy gender and age frequency matched population Caucasian controls to investigate the association between the MDM2 SNP309 and the risk of developing early onset lung cancer. Conditional logistic models were applied to assess the genotype-phenotype association, adjusted for smoking.
Compared to the GG genotype, the adjusted ORs for the TG and TT genotype were 0.9 (95% CI: 0.7–1.5) and 1.0 (95% CI: 0.7–1.5), respectively. Also no association was found for histological subtypes of lung cancer. The strength of this study is that within young cases the genetic component to develop lung cancer may be greater. Our results indicate that the MDM2 SNP309 is not significantly associated with lung carcinogenesis but point towards gender-specific differences.
Literature
1.
Momand J, Zambetti GP: Mdm-2: "big brother" of p53. J Cell Biochem. 1997, 64: 343-352. 10.1002/(SICI)1097-4644(19970301)64:3<343::AID-JCB1>3.0.CO;2-V.CrossRefPubMed
2.
Freedman DA, Wu L, Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999, 55: 96-107. 10.1007/s000180050273.CrossRefPubMed
3.
Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature. 1997, 387: 299-303. 10.1038/387299a0.CrossRefPubMed
4.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004, 119: 591-602. 10.1016/j.cell.2004.11.022.CrossRefPubMed
5.
Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H: Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer. 2006, 118: 1275-1278. 10.1002/ijc.21463.CrossRefPubMed
6.
Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A: Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer. 2006, 119: 718-721. 10.1002/ijc.21872.CrossRefPubMed
7.
Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D: Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006, 27: 110-117. 10.1002/humu.20277.CrossRefPubMed
8.
Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC: MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1559-1561. 10.1158/1055-9965.EPI-06-0217.CrossRefPubMed
9.
Holle R, Happich M, Lowel H, Wichmann HE: KORA--a research platform for population based health research. Gesundheitswesen. 2005, 67 : S19-S25.CrossRefPubMed
10.
Wichmann HE, Gieger C, Illig T: KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen. 2005, 67 Suppl 1: S26-S30.CrossRefPubMed
11.
Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A: The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003, 13: 607-618. 10.1097/00008571-200310000-00004.CrossRefPubMed
12.
Steffens M, Lamina C, Illig T, Bettecken T, Vogler R, Entz P, Suk EK, Toliat MR, Klopp N, Caliebe A, Konig IR, Kohler K, Ludemann J, Lacava AD, Fimmers R, Lichtner P, Ziegler A, Wolf A, Krawczak M, Nurnberg P, Hampe J, Schreiber S, Meitinger T, Wichmann HE, Roeder K, Wienker TF, Baur MP: SNP-based analysis of genetic substructure in the German population. Hum Hered. 2006, 62: 20-29. 10.1159/000095850.CrossRefPubMed
13.
Weidinger S, Klopp N, Wagenpfeil S, Rummler L, Schedel M, Kabesch M, Schafer T, Darsow U, Jakob T, Behrendt H, Wichmann HE, Ring J, Illig T: Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet. 2004, 41: 658-663. 10.1136/jmg.2004.020263.CrossRefPubMedPubMedCentral
14.
Rosenbaum PR, Donald BR: The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika. 1983, 70: 41-55. 10.1093/biomet/70.1.41.CrossRef
15.
Slager SL, Schaid DJ: Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered. 2001, 52: 149-153. 10.1159/000053370.CrossRefPubMed
16.
Park SH, Choi JE, Kim EJ, Jang JS, Han HS, Lee WK, Kang YM, Park JY: MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer. 2006, 54: 19-24. 10.1016/j.lungcan.2006.06.008.CrossRefPubMed
17.
Jun HJ, Park SH, Lee WK, Choi JE, Jang JS, Kim EJ, Cha SI, Kim DS, Kam S, Kim CH, Kang YM, Jung TH, Park JY: Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog. 2007, 46: 100-105. 10.1002/mc.20279.CrossRefPubMed
18.
Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q: MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis. 2006, 27: 2028-2033. 10.1093/carcin/bgl047.CrossRefPubMed
19.
Jun HJ, Park SH, Lee WK, Choi JE, Jang JS, Kim EJ, Cha SI, Kim DS, Kam S, Kim CH, Kang YM, Jung TH, Park JY: Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog. 2006
20.
Wilkening S, Bermejo JL, Hemminki K: MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007, 28: 2262-2267. 10.1093/carcin/bgm191.CrossRefPubMed
21.
Liu G, Wheatley-Price P, Zhou W, Park S, Heist RS, Asomaning K, Wain JC, Lynch TJ, Su L, Christiani DC: Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer. 2008, 122: 915-918. 10.1002/ijc.23178.CrossRefPubMed
22.
Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ: MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006, 66: 5104-5110. 10.1158/0008-5472.CAN-06-0180.CrossRefPubMed
23.
Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ: MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet. 2006, 43: 950-952. 10.1136/jmg.2006.043539.CrossRefPubMedPubMedCentral
24.
Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM: Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer. 2007, 46: 239-247. 10.1002/gcc.20407.CrossRefPubMed
25.
Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R: MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007, 13: 4123-4129. 10.1158/1078-0432.CCR-07-0609.CrossRefPubMed
Metadata
Title
Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene
Authors
Kirstin Mittelstrass
Wiebke Sauter
Albert Rosenberger
Thomas Illig
Maria Timofeeva
Norman Klopp
Hendrik Dienemann
Eckart Meese
Gerhard Sybrecht
Gabi Woelke
Mathias Cebulla
Maria Degen
Harald Morr
Peter Drings
Andreas Groeschel
Karsten Grosse Kreymborg
Karl Haeußinger
Gerd Hoeffken
Christine Schmidt
Bettina Jilge
Wilhelm Schmidt
You-Dschun Ko
Dagmar Taeuscher
Jenny Chang-Claude
Heinz-Erich Wichmann
Heike Bickeboeller
Angela Risch
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-113

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism

Research article

Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice

Research article

mRNA expression of the DNA replication-initiation proteins in epithelial dysplasia and squamous cell carcinoma of the tongue

Research article

Muscle invasive bladder cancer in Upper Egypt: the shift in risk factors and tumor characteristics

Research article

Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancer

Research article

Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits